Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses...

Area of Science:

• Immunology
• Pharmacology

Background:

• Co-stimulation blockade is a key strategy for autoimmune diseases and transplant rejection.
• Small molecule inhibitors targeting CD80 (B7-1) have emerged as potential therapeutics.
• RhuDex is a compound designed to inhibit T cell co-stimulation.

Purpose of the Study:

• To evaluate RhuDex's reactivity with rhesus monkey CD80.
• To assess RhuDex's in vitro biological effects on rhesus monkey lymphocytes.
• To determine RhuDex's efficacy in suppressing inflammatory responses in vivo.

Main Methods:

• In vitro T cell co-stimulation assay using rhesus monkey lymphocytes.
• Assessment of proinflammatory cytokine release and cellular proliferation.
• In vivo evaluation of RhuDex's effect on protein-induced delayed type hypersensitivity (DTH) response in rhesus monkeys.

Main Results:

• RhuDex demonstrated micromolar potency in inhibiting proinflammatory cytokine release and cellular proliferation in vitro.
• Systemic administration of RhuDex significantly suppressed the DTH response in rhesus monkeys.
• These findings indicate RhuDex's potential to modulate autoimmune-mediated inflammatory processes.

Conclusions:

• RhuDex effectively inhibits T cell co-stimulation and inflammatory responses in a non-human primate model.
• The compound shows promise for clinical applications in autoimmune diseases and transplant rejection.
• Targeting CD80 upregulation with RhuDex may be a viable therapeutic strategy.